Paulson Richard A. 4
4 · Karyopharm Therapeutics Inc. · Filed Feb 9, 2026
Research Summary
AI-generated summary of this filing
Karyopharm (KPTI) CEO Richard Paulson Receives RSU Award
What Happened
Richard A. Paulson, President and CEO and a director of Karyopharm Therapeutics Inc. (KPTI), was granted 81,060 restricted stock units (RSUs) on February 5, 2026. The award was recorded as an acquisition (transaction code A) at $0.00 per share (i.e., no cash paid by the insider). The RSUs convert one-for-one into common stock when they vest.
Key Details
- Transaction date: 2026-02-05 (Form 4 filed 2026-02-09). No indication in the provided data that the filing was late.
- Security and amount: 81,060 RSUs granted, acquisition price listed as $0.00.
- Shares owned after transaction: Not specified in the provided filing.
- Footnote: RSUs awarded under the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan; RSUs convert one-for-one to common stock. Vesting: 50% on Jan 31, 2027 and 50% on Jan 31, 2028 (see F1).
Context
RSU grants are a form of equity compensation and do not represent an immediate purchase or sale of shares. These RSUs will only become actual shares (and tradable) as they vest according to the schedule above. For retail investors, awards signal management compensation alignment but are not the same as insider purchases where executives put personal capital at risk.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-05+81,060→ 279,391 total
Footnotes (1)
- [F1]Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on January 31, 2027, with the remaining 50% vesting on January 31, 2028.